Sapanisertib

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameSapanisertib
Drug Alias NameSapanisertibum沙帕色替沙帕舍替Oral mTORC1/2 inhibitor MLN0128 - Millennium PharmaceuticalsDual TORC1/2 inhibitor - Millennium Pharmaceuticals +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Brain metastasesMetastatic breast cancer +[68] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteTakeda Pharmaceuticals International, IncNational Cancer Institute +[7] 
Inactive CompaniesFaeth Therapeutics IncUniversity Of Colorado Denver
Active IndicationsPancreatic neuroendocrine tumors (pNET)Brain metastasesSolid tumours +[50] 
Inactive IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantGenital Neoplasms, Male +[18] 

Other Information

ATC CodeN/A
Related LinksN/A